In a filing to SGX on Monday, the group did not elaborate on reasons for the decline.
SINGAPORE (Oct 30): Tianjin Zhong Xin Pharmaceutical Group Corporation posts an 11% decline in earnings to RMB 82.0 million ($16.8 million) for the 3Q ended September, from RMB 91.6 million a year ago.
Revenue fell 14% to RMB 1.31 billion in 3Q17, from RMB 1.51 billion a year ago.
